Welcome to our dedicated page for OS Therapies Incorporated news (Ticker: OSTX), a resource for investors and traders seeking the latest updates and insights on OS Therapies Incorporated stock.
OSTX (OS Therapies, Inc.) is an innovative biotechnology company committed to developing advanced therapies for the treatment of osteosarcoma, a rare and aggressive bone cancer primarily affecting children and young adults. The company leverages cutting-edge research and technology to create targeted treatments aimed at improving patient outcomes and quality of life.
OSTX's core business involves the development of novel immunotherapies and precision medicine. The company's flagship project, OST-01, is a groundbreaking immunotherapy designed to specifically target and eliminate osteosarcoma cells while sparing healthy tissue. This pioneering approach has shown promising results in preclinical studies and is currently in the early stages of clinical trials.
Recently, OS Therapies has secured significant funding and established strategic partnerships with leading research institutions and pharmaceutical companies. These collaborations are aimed at accelerating the development and commercialization of their therapeutic pipeline.
Financially, OS Therapies, Inc. has demonstrated robust growth and stability. The company's recent funding rounds have attracted major investors, underscoring confidence in OSTX's potential. This financial backing enables OSTX to expand its research efforts and bring its innovative treatments to market more rapidly.
OS Therapies is also actively engaged in several promising projects beyond OST-01. These include exploratory research into other rare cancers and potential applications of their immunotherapy platform. The company's commitment to scientific excellence and patient care continues to drive its mission forward.
Overall, OSTX is a key player in the biotechnology sector, dedicated to transforming the landscape of cancer treatment through innovation and collaboration. For investors and stakeholders, OS Therapies offers a compelling opportunity in the promising field of cancer immunotherapy.
OS Therapies (NYSE-A: OSTX) announced positive results from its Phase 2b clinical trial of OST-HER2, showing statistically significant outcomes in treating recurrent, fully resected, lung metastatic osteosarcoma. The trial achieved its primary endpoint with 33.3% event-free survival (EFS) at 12 months compared to 20% historical control (p=0.0158).
The study demonstrated promising interim results for overall survival (OS), with 91% one-year survival and 61% two-year survival rates, compared to historical controls of 80% and 40% respectively. All patients achieving 12-month EFS remain alive in follow-up. The trial included 39 evaluable patients aged 12-39 years across 21 centers, with treatment consisting of 16 doses over 48 weeks.
Post-hoc analyses revealed higher EFS rates in females (47%) compared to males (20%), and better outcomes in patients with multiple prior lung resections (55%) versus single resection (25%). The treatment demonstrated a favorable safety profile in this population with no currently approved therapies.
OS Therapies (NYSE-A: OSTX) announced its CEO Paul Romness will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025. Following their 2024 IPO and completion of Phase 2b clinical trial for OST-HER2 in treating recurrent, resected metastatic Osteosarcoma, the company plans to release trial data updates during the conference week.
The company anticipates potential FDA approval in 2025, which could earn them a Priority Review Voucher (PRV) valued at approximately $150 million. This voucher could be sold to fund OST-HER2's development for other HER2-positive cancers like Breast and Colorectal cancer. Despite recent changes in PRV program reauthorization, OS Therapies remains eligible for the voucher due to receiving rare pediatric disease designation before December 20, 2024, with approval targeted before September 30, 2026.
OS Therapies (NYSE-A: OSTX) has closed a $6 million private placement financing, with 98% of investment coming from Pre-IPO and/or IPO investors. The company sold 1.5 million units at $4.00 per unit, each consisting of one share of Series A Senior Convertible Preferred Stock and one warrant to purchase common stock at $4.40.
The funding is expected to provide cash runway into 2026, primarily supporting clinical and regulatory milestones for OST-HER2, their lead therapeutic candidate for recurrent, resected metastatic osteosarcoma. The company aims for commercialization in 2025 and remains eligible for a Priority Review Voucher (PRV), currently valued at approximately $150 million, which could fund expansion into other HER2 positive cancers.
OS Therapies (NYSE-A: OSTX) has partnered with B2i Digital to enhance investor outreach and raise awareness about its cancer immunotherapy research. The company's lead candidate, OST-HER2, is an off-the-shelf immunotherapy targeting HER2-positive cancer cells, currently in Phase 2b trials for recurrent, resected metastatic osteosarcoma. The trial has completed enrollment and patient visits, with clinical data updates expected during the JP Morgan Healthcare Conference 2025.
Additionally, OS Therapies is developing a tunable Antibody-Drug Conjugate (ADC) platform aimed at providing tailored cancer treatments with improved efficacy and reduced side effects. B2i Digital will implement data-driven strategies to communicate the company's progress and upcoming milestones to investors.
OS Therapies (NYSE-A: OSTX) has announced a $6 million private placement, selling 1.5 million units at $4.00 per unit. Each unit includes one share of Series A Senior Convertible Preferred Stock and one warrant to purchase common stock. The Preferred Stock conversion price is $4.00, with warrants exercisable at $4.40 per share.
The placement, expected to close around December 27, 2024, will provide funding into 2026. The proceeds will support clinical and regulatory milestones for OST-HER2, the company's lead therapeutic candidate for recurrent, resected metastatic osteosarcoma. Phase 2b data for OST-HER2 will be announced during the JP Morgan Healthcare Conference in January 2025.
OS Therapies (NYSE-A: OSTX) reported Q3 2024 financial results and business updates. The company completed its IPO and finished dosing the final patient in its Phase 2b clinical trial of OST-HER2 in osteosarcoma. Topline data is expected in December 2024. The trial treated 41 patients across 21 US sites. The company reported a net operating loss of $2.875 million in Q3 2024, compared to $2.006 million in Q3 2023, with a net loss per share of $0.18. OST-HER2 has received Rare Pediatric Disease, Fast Track, and Orphan Drug Designations from FDA and EMA.
OS Therapies (NYSE-A: OSTX) has announced its participation in The Spartan Capital Investor Conference on November 4, 2024, at the Pierre Hotel in New York. CEO Paul Romness and CBO Gerald Commissiong will deliver a corporate overview at 4:45 PM ET and will be available for one-on-one meetings with registered investors.
The conference, organized with B2i Digital, will showcase presentations from over 30 selected companies and feature panel discussions, meetings, and networking opportunities. This participation demonstrates OS Therapies' commitment to engaging with industry leaders and investors.
OS Therapies (NYSE: OSTX) announces an exclusive live investor webinar scheduled for October 30, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature presentations from CEO Paul Romness and CBO Gerald Commissiong focusing on the company's novel treatments for Osteosarcoma and solid tumors through OST-HER2 and OST-tADC candidates. The company highlights potential near-term revenue opportunities including out-licensing deals for canine OS ($15M+), human OS ($100M+), OST-tADC SiLinkers™ ($20-80M), and a priority review voucher valued at $100-110M.
OS Therapies (NYSE American: OSTX), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, has announced its participation in the LD Micro Main Event XVII. CEO Paul Romness and CBO Gerald Commissiong will deliver a corporate overview presentation on Tuesday, October 29, 2024, at 11:30 AM PT at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference runs from October 28-30, 2024. Both executives will be available for one-on-one meetings with registered conference investors.
OS Therapies (NYSE American: OSTX), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's CEO, Paul Romness, will be presenting in a fireside chat during the event.
Key details of the presentation:
- Event: Fireside Chat at 2024 Maxim Healthcare Virtual Summit
- Date: Thursday, October 17, 2024
- Time: 3:00 PM ET
The summit is scheduled to take place virtually from October 15 to 17, 2024. Interested parties can access the webcast of the fireside chat through the provided link: https://m-vest.com/events/healthcare-10152024
FAQ
What is the current stock price of OS Therapies Incorporated (OSTX)?
What is the market cap of OS Therapies Incorporated (OSTX)?
What does OS Therapies, Inc. specialize in?
What is OSTX's flagship project?
How is OS Therapies funded?
What are some of OS Therapies' recent achievements?
What is the current status of OST-01?
What other projects is OS Therapies working on?
How does OS Therapies contribute to the field of cancer treatment?
Who are OS Therapies' partners?
What is the significance of OS Therapies' work?
Why should investors be interested in OSTX?
